Molecular diagnostics

Point of Care (POC) Molecular Diagnostics Global Market Report 2022: Rising Demand for Point of Care Diagnostics Augurs Well for Sector - ResearchAndMarkets.com

Retrieved on: 
Friday, August 26, 2022
Health, Other Health, ISH, COVID-19, Awareness, Infection, Molecular diagnostics, Prevalence, CAGR, Cancer, Biomarker, Point, POC, Growth, Proteomics, Medical imaging, Pharmaceutical industry, Pet

The "Point of Care (POC) Molecular Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Point of Care (POC) Molecular Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Increasing prevalence of various cancers and infectious disease types constitutes the major factor to drive growth for the market for the market in the coming years.
  • Increasing use of molecular diagnostics for home healthcare is another important growth driving factor for the market.
  • The growing application of healthcare information technology for providing accurate diagnostics constitutes yet another factor supporting growth for molecular diagnostics market.

QIAGEN Issues 2021 Sustainability Report

Retrieved on: 
Thursday, August 18, 2022
Research, Professional Services, Oil, Gas, Sustainability, Training, Energy, Medical Devices, Environment, Education, Science, Biotechnology, Health, Environmental, Social and Governance (ESG), Social Security Government Pension Offset, Woman, U.S. Securities and Exchange Commission, Climate change, Budget, Carbon, NYSE, Social, CEO, Cervical cancer, Growth, Sustainalytics, SEC, HPV, Tuberculosis, Life, ESG, Blood, Language, Export Management and Compliance Program, DNA, List of life sciences, LED, Lighting, RNA, Risk, Electricity, Research, Knowledge, Health, Automation, QGEN, Sustainability reporting, Goal, Protein, ISO, ISS, Molecular diagnostics, Solution, TB, QFT, Disease, Lithium, Medical device, Fine chemical, Insight, QIAGEN, MSCI, Environment

In 2021, QIAGEN lowered its greenhouse gas intensity, i.e., its Scope 1 and 2 emissions divided by net sales, by 16% compared to the previous year.

Key Points: 
  • In 2021, QIAGEN lowered its greenhouse gas intensity, i.e., its Scope 1 and 2 emissions divided by net sales, by 16% compared to the previous year.
  • For example, QIAGEN introduced plant-based material alternatives either based on straw or paper to replace the expanded polystyrene coolers in cold-chain shipments in 2021.
  • QIAGEN launched QIAreach QuantiFERON-TB (QIAreach QFT), a test featuring ultrasensitive digital detection built into a fully portable device, in October 2021.
  • For its sustainability efforts QIAGEN was recognized by the rating agencies ISS-ESG, MSCI as well as Sustainalytics which all specialize in sustainability.

Companion Animal Diagnostics Market to Reach USD 6.88 Billion, Globally, by 2031 at 8.6% CAGR: Allied Market Research

Retrieved on: 
Wednesday, August 17, 2022
NCBI, Rabies virus, Zoonosis, Industry, Diagnosis, Population, Technology, Growth, Dog, Cat, Incidence, Prevalence, Income, Clinical urine tests, Conditional sentence, Skin, Awareness, Infection, CAGR, Severe acute respiratory syndrome coronavirus 2, Research, COVID-19, Molecular diagnostics, Animal, Health, Adoption, Medical device, Vaccine, Pet, Hematology, Virology, Parasitology, University, Bacteriology

PORTLAND, Ore., Aug. 17, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, 'Companion Animal Diagnostics Market By Technology (Clinical Biochemistry, Immunodiagnostics, Molecular Diagnostics, Hematology, Urinalysis, Others), By Application (Clinical Pathology, Bacteriology, Virology, Parasitology, Other Applications), By Animal Type (Dogs, Cats, Others), By End User (Diagnostic Labs, Veterinary Hospitals and Clinics, Point-Of-Care and In-House Testing, Research Institutes and Universities): Global Opportunity Analysis and Industry Forecast, 2021-2031.' According to the report, the global companion animal diagnostics industry was estimated at $2.99 billion in 2021, and is anticipated to hit $6.88 billion by 2031, registering a CAGR of 8.6% from 2022 to 2031. The report offers an explicit analysis of the changing market trends, top segments, key investment pockets, value chain, competitive scenario, and regional landscape. The market study is exclusively meant to help the readers with a complete valuation of industry analysis and trends.

Key Points: 
  • According to the report, the global companion animal diagnostics industry was estimated at $2.99 billion in 2021, and is anticipated to hit $6.88 billion by 2031, registering a CAGR of 8.6% from 2022 to 2031.
  • This factor had a positive impact on the global companion animal diagnostics market.
  • Based on technology, the clinical biochemistry segment held around one-third of the global companion animal diagnostics market revenue in 2021, and is expected to lead the trail by 2031.
  • By animal type, the dogs segment contributed to nearly half of the global companion animal diagnostics market share in 2021, and is expected to retain its dominance by 2031.

Companion Animal Diagnostics Market to Reach USD 6.88 Billion, Globally, by 2031 at 8.6% CAGR: Allied Market Research

Retrieved on: 
Wednesday, August 17, 2022
NCBI, Rabies virus, Zoonosis, Industry, Diagnosis, Population, Technology, Growth, Dog, Cat, Incidence, Prevalence, Income, Clinical urine tests, Conditional sentence, Skin, Awareness, Infection, CAGR, Severe acute respiratory syndrome coronavirus 2, Research, COVID-19, Molecular diagnostics, Animal, Health, Adoption, Medical device, Vaccine, Pet, Hematology, Virology, Parasitology, University, Bacteriology

PORTLAND, Ore., Aug. 17, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, 'Companion Animal Diagnostics Market By Technology (Clinical Biochemistry, Immunodiagnostics, Molecular Diagnostics, Hematology, Urinalysis, Others), By Application (Clinical Pathology, Bacteriology, Virology, Parasitology, Other Applications), By Animal Type (Dogs, Cats, Others), By End User (Diagnostic Labs, Veterinary Hospitals and Clinics, Point-Of-Care and In-House Testing, Research Institutes and Universities): Global Opportunity Analysis and Industry Forecast, 2021-2031.' According to the report, the global companion animal diagnostics industry was estimated at $2.99 billion in 2021, and is anticipated to hit $6.88 billion by 2031, registering a CAGR of 8.6% from 2022 to 2031. The report offers an explicit analysis of the changing market trends, top segments, key investment pockets, value chain, competitive scenario, and regional landscape. The market study is exclusively meant to help the readers with a complete valuation of industry analysis and trends.

Key Points: 
  • According to the report, the global companion animal diagnostics industry was estimated at $2.99 billion in 2021, and is anticipated to hit $6.88 billion by 2031, registering a CAGR of 8.6% from 2022 to 2031.
  • This factor had a positive impact on the global companion animal diagnostics market.
  • Based on technology, the clinical biochemistry segment held around one-third of the global companion animal diagnostics market revenue in 2021, and is expected to lead the trail by 2031.
  • By animal type, the dogs segment contributed to nearly half of the global companion animal diagnostics market share in 2021, and is expected to retain its dominance by 2031.

QIAGEN Launches Syndromic Test for QIAstat-Dx Device to Combat Global Monkeypox Health Emergency

Retrieved on: 
Monday, August 15, 2022
Health, Infectious Diseases, Clinical Trials, Research, Pharmaceutical, Science, U.S. Securities and Exchange Commission, Â, Monkeypox, Union, Public health, Laboratory, World Health Organization, Budget, VZV, NYSE, Senior, HSV2, Growth, SEC, Research, Life, Government, Blood, European, DNA, COVID-19, Infection, Urinary tract infection, QIAGEN, List of life sciences, HH6, RNA, RUO, Gold standard (test), Herpes labialis, Enterovirus, Knowledge, WHO, World, Automation, QGEN, Meningitis, Protein, Monkeypox virus, Molecular diagnostics, PCR, Solution, LDT, HSV1, Vaccine, Pharmaceutical industry, Insight

The new panel currently for research use only (RUO) comes in cartridge form to run on QIAGENs QIAstat-Dx automated syndromic testing devices.

Key Points: 
  • The new panel currently for research use only (RUO) comes in cartridge form to run on QIAGENs QIAstat-Dx automated syndromic testing devices.
  • Currently the worlds only syndromic test for the pathogen, the panel will prove to be crucial for detecting and then combatting the spread of monkeypox around the globe.
  • The panels RUO-status means it currently can only be used for the surveillance not screening or diagnosing of monkeypox cases.
  • QIAGEN teams around the world are working with healthcare authorities to support testing for the monkeypox virus outbreak.

City of Hope Researchers Have Developed a Blood Test That May Screen for Early-onset Colorectal Cancer

Retrieved on: 
Wednesday, August 10, 2022
Research, Genetics, Millennials, Biotechnology, Generation Z, Health, Consumer, Science, Oncology, Haematopoietic system, Experiment, CAR, Gene, Diagnosis, Gene expression, Technology, YouTube, Cancer, Large intestine, Research, Department, City of Hope, Colorectal cancer, Patient, Therapy, Instagram, Twitter, Data, Translational Genomics Research Institute, Cancer Treatment Centers of America, National, National Cancer Institute, MicroRNA, Immunotherapy, City, National Institutes of Health, Colon, Diabetes, Molecular diagnostics, LinkedIn, Liquid biopsy, Mirna, Organization, Medical imaging, Pharmaceutical industry, Facebook, Gastroenterology

Colorectal cancer is the fourth most common cancer , according to the U.S. Centers for Disease Control and Prevention.

Key Points: 
  • Colorectal cancer is the fourth most common cancer , according to the U.S. Centers for Disease Control and Prevention.
  • As a result, the recommendation to begin regular colorectal cancer screening has been moved to start five years earlier at age 45.
  • They extrapolated the data of patients with either Stage 1 or 2 early-onset colorectal cancer (42) or patients with late-onset colorectal cancer (370).
  • To enhance specificity and accuracy, the researchers eliminated all miRNA markers shared by people with early- and late-onset colorectal cancer to better identify patients with early-onset colorectal cancer.

Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development

Retrieved on: 
Wednesday, August 10, 2022
Oncology, Health, Infectious Diseases, Research, Science, Pharmaceutical, Biotechnology, Antibody, Multimedia, LNO, Intel, Commercialization, Johnson & Johnson, Drug discovery, Cell biology, Senior, Nobel Prize, 3D, Cisco Systems, Technology, CA, SVP, Leadership, GSK, Board, Tissue, Externalization, Apple, Merck, Patient, Celesta, Pharmacology, Innovation, Khosla Ventures, Therapy, Vaccine, Amgen, Biopharmaceutical, Doctor of Philosophy, Novartis, SOSV, Avidity, Yale University, Flex, Software, Molecular diagnostics, Semiconductor, Sterling, Pharmaceutical industry, Management, San Francisco Bay Area

The capital will be used to expand Prellis Bios proprietary, first-in-class human immune system-based drug discovery and development platform, EXIS (Externalized Human Immune System).

Key Points: 
  • The capital will be used to expand Prellis Bios proprietary, first-in-class human immune system-based drug discovery and development platform, EXIS (Externalized Human Immune System).
  • This new chapter and investment will enable our team to bring better medicines to patients who desperately need them.
  • Prellis proprietary platform Externalized Immune System, EXIS, precisely reproduces the human immune response through the creation of lymph node organoids (LNOs).
  • Prellis is dedicated to improving patients' lives by addressing challenges commonly faced in early-stage drug discovery and translational pharmacology.

Genetic Testing Global Market Report 2022: Featuring Key Players Abbott Laboratories, Danaher Corporation, Illumina, BioRad Laboratories & F Hoffmann-La Roche - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 27, 2022
Health, Genetics, DNA, Consciousness, Diagnosis, Investment, Awareness, Mortality, Molecular diagnostics, Research, Government, Genetics, Genetic testing, Workforce, RAD51C, Lists of diseases, Prenatal development, COVID-19, Classification, Cancer, Gene, Cell, Disease, Patient, Power, Mindfulness, Ovarian cancer, Breast, Medicine, Agriculture, Vaccine, Pharmaceutical industry, Growth

The "Genetic Testing Market Global Forecast 2021-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Genetic Testing Market Global Forecast 2021-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Prominently, the global genetic testing market is driven by the increasing number of patients with genetic diseases and increasing healthcare expenditure by significant economies across the globe.
  • Besides, the growing awareness about genetic conditions, rising investments in research and development, and increasing government support further fuel the market growth.
  • For instance, molecular technology is used in genetic tests such as carrier testing, diagnostic testing, predictive & pre-symptomatic testing.

BD, CerTest Biotec Announce Commercial Launch of Monkeypox Test

Retrieved on: 
Wednesday, July 27, 2022
Monkeypox virus, World, Laboratory, Twitter, Molecular diagnostics, NYSE, Research, BDX, Solution, Health, Monkeypox, Safety, COVID-19, World Health Organization, Urinary tract infection, Organization, Becton, TNA, Disease, Company, Patient, LinkedIn, Efficiency, Therapy, Infection, PCR, BD, Becton, Dickinson and Company headquarters, Pharmaceutical industry, Computer data storage, Vaccine

FRANKLIN LAKES, N.J., July 27, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and CerTest Biotec today announced their newly developed molecular polymerase chain reaction (PCR) test for the monkeypox virus is now commercially available outside of the United States for use in research applications by laboratories.

Key Points: 
  • The assay leveraged the BD MAX System open system reagent suite to develop the CerTest VIASURE Monkeypox molecular test on the BD MAX System.
  • "We hope this new test will boost capacity for monkeypox research, ultimately helping quell the spread of the disease."
  • As with all CerTest tests, the Monkeypox PCR Detection Kit for the BD MAX System is offered in a lyophilized format.
  • CerTest Biotec is a European company established in 2002 for the development and manufacturing of in vitro diagnostic medical devices.

QIAGEN adds new biopharma products to QIAcuity digital PCR portfolio and launches Expert Custom Assay Design Service

Retrieved on: 
Wednesday, July 27, 2022
Software, Biotechnology, Pharmaceutical, General Health, Health, Technology, Genetics, Other Technology, DNA, Escherichia coli, HEK293, Biopharma LLC, Center, Education, Communities and Justice Directorates, Protein, U.S. Securities and Exchange Commission, Molecular diagnostics, CHO, Real-time, NYSE, SEC, QGEN, Research, Drug discovery, Compliance, Software, Solution, Gene, Title 21 CFR Part 11, Polymerase, Knowledge, GMP, Catalog, Automation, Central business district, Drug development, Technology, CGT, FDA, Senior, Blood, CFR, Life, HEK 293 cells, Growth, PCR, Workflow, Budget, AAV, RNA, Vaccine, Medical device, Fine chemical, QIAGEN, Insight, Academy, Pharma

A new version of the QIAcuity Software Suite has been released with expanded functionality to support good manufacturing practice (GMP) compliance.

Key Points: 
  • A new version of the QIAcuity Software Suite has been released with expanded functionality to support good manufacturing practice (GMP) compliance.
  • QIAcuitys approach to digital PCR is based on using nanoplates to partition the samples more quickly than other systems.
  • Our custom assays for dPCR build on decades of expertise in assay design for traditional qPCR.
  • The Expert Custom Assay Design Service will extend customer choice beyond the existing catalog of assays, especially in key application areas that require simultaneous detection of up to five molecular markers.